Reported cash
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Price chart
What changed?
No verified development in tracked sources.
Upcoming catalysts
Next verified event · Expected FDA action
ABP 206 · By year-end 2026
treatment-naïve unresectable or metastatic melanoma
Announced Nov 3, 2026 · Announced window
Official announcementSource wording
•A randomized, double-blind comparative clinical study of ABP 206 compared with OPDIVO® (nivolumab) is ongoing in patients with treatment-naïve unresectable or metastatic melanoma. The Biologics License Application (BLA) with the FDA has been submitted and accepted for review. The Company expects an FDA action on this BLA by the end of the year.
Drug pipeline
0 programs · 0 verified studies
No verified studies linked yet.
1602 unverified sponsor matches remain unlinked.
Verified timeline
0 recordsNo verified developments in tracked sources.